Business Description
Perspective Therapeutics Inc
NAICS : 339112
SIC : 5047
ISIN : US46489V1044
Description
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 75.58 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 11.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -43.7 | |||||
| 3-Year EPS without NRI Growth Rate | -40.9 | |||||
| 3-Year FCF Growth Rate | -34.8 | |||||
| 3-Year Book Growth Rate | 47.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.82 | |||||
| 9-Day RSI | 48.36 | |||||
| 14-Day RSI | 49.34 | |||||
| 6-1 Month Momentum % | 39.43 | |||||
| 12-1 Month Momentum % | 444.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 27.73 | |||||
| Quick Ratio | 27.73 | |||||
| Cash Ratio | 27.6 | |||||
| Days Inventory | 365.21 | |||||
| Days Payable | 1685.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.9 | |||||
| Shareholder Yield % | -32.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 135.17 | |||||
| Operating Margin % | 1394.93 | |||||
| Net Margin % | 1772.34 | |||||
| FCF Margin % | 757.78 | |||||
| ROE % | -34.58 | |||||
| ROA % | -29.72 | |||||
| ROIC % | -60.43 | |||||
| 3-Year ROIIC % | -42.64 | |||||
| ROC (Joel Greenblatt) % | -382.03 | |||||
| ROCE % | -22.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.64 | |||||
| Price-to-Tangible-Book | 3.34 | |||||
| EV-to-EBIT | -14.59 | |||||
| EV-to-EBITDA | -15.1 | |||||
| EV-to-Revenue | -183.53 | |||||
| EV-to-Forward-Revenue | 607.52 | |||||
| EV-to-FCF | -24.87 | |||||
| Price-to-Projected-FCF | 5.39 | |||||
| Price-to-Net-Current-Asset-Value | 3.58 | |||||
| Price-to-Net-Cash | 3.6 | |||||
| Earnings Yield (Greenblatt) % | -6.85 | |||||
| FCF Yield % | -2.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Perspective Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | -3.015 | ||
| EPS (TTM) (€) | -1.551 | ||
| Beta | 2.4 | ||
| Volatility % | 122.27 | ||
| 14-Day RSI | 49.34 | ||
| 14-Day ATR (€) | 0.353614 | ||
| 20-Day SMA (€) | 12.445 | ||
| 12-1 Month Momentum % | 444.64 | ||
| 52-Week Range (€) | 1.99 - 17.2 | ||
| Shares Outstanding (Mil) | 67.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Perspective Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Perspective Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Perspective Therapeutics Inc Frequently Asked Questions
What is Perspective Therapeutics Inc(FRA:AAJ0)'s stock price today?
The current price of FRA:AAJ0 is €12.30. The 52 week high of FRA:AAJ0 is €17.20 and 52 week low is €1.99.
When is next earnings date of Perspective Therapeutics Inc(FRA:AAJ0)?
The next earnings date of Perspective Therapeutics Inc(FRA:AAJ0) is 2024-11-14 Est..
Does Perspective Therapeutics Inc(FRA:AAJ0) pay dividends? If so, how much?
Perspective Therapeutics Inc(FRA:AAJ0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers